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Abstract 
Background: Known risk factors for secondary lymphedema only partially explain 
who develops lymphedema following cancer, suggesting that inherited genetic 
susceptibility may influence risk.  Moreover, identification of molecular signatures 
could facilitate lymphedema risk prediction prior to surgery or lead to effective drug 
therapies for prevention or treatment. Recent advances in the molecular biology 
underlying development of the lymphatic system and related congenital disorders 
implicate a number of potential candidate genes to explore in relation to secondary 
lymphedema.  
Methods and Results: We undertook a nested case-control study, with participants 
who had developed lymphedema after surgical intervention within the first 18 months 
of their breast cancer diagnosis serving as cases (n=22) and those without 
lymphedema serving as controls (n=98), identified from a prospective, population-
based, cohort study in Queensland, Australia.  TagSNPs that covered all known 
genetic variation in the genes SOX18, VEGFC, VEGFD, VEGFR2, VEGFR3, RORC, 
FOXC2, LYVE1, ADM and PROX1 were selected for genotyping. Multiple SNPs 
within three receptor genes, VEGFR2, VEGFR3 and RORC, were associated with 
lymphedema defined by statistical significance (p<0.05) or extreme risk estimates 
(OR<0.5 or >2.0).  
Conclusions: These provocative, albeit preliminary, findings regarding possible 
genetic predisposition to secondary lymphedema following breast cancer treatment 
warrant further attention for potential replication using larger datasets. 
 
Condensed Abstract 
We undertook a nested case-control study, with participants who developed 
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lymphedema after breast cancer surgery serving as cases (n=22) and those without 
lymphedema serving as controls (n=98), identified from a prospective cohort study.  
TagSNPs that covered all known genetic variation in the genes SOX18, VEGFC, 
VEGFD, VEGFR2, VEGFR3, RORC, FOXC2, LYVE1, ADM and PROX1 were 
selected for genotyping. Multiple SNPs within VEGFR2, VEGFR3 and RORC, were 
associated with lymphedema defined by statistical significance (p<0.05) or extreme 
risk estimates (OR<0.5 or >2.0). These results provide provocative, albeit 
preliminary, findings in the identification of molecular signatures that could facilitate 
lymphedema risk prediction.  
 
 
Keywords: breast cancer, lymphedema, genetic predisposition, risk factors 
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Introduction 
Lymphedema is one of the most problematic complications following breast cancer 
treatment, experienced by approximately 30% of breast cancer survivors.1-3 It 
represents failure of the lymphatic system to adequately drain fluid and proteins from 
the interstitial tissue and to circulate lymphocytes. Removal or damage to the lymph 
nodes or lymphatic vasculature during cancer treatment may impede proper 
physiological function of this network. Although lymphedema can occur in any part 
of the body, it generally refers to an accumulation of fluid and subsequent distortion 
of a limb.4 Little is known about its prevention, and it is regarded as an incurable, 
progressive, disfiguring and disabling disorder that is difficult to manage, 
compromising function5 and quality of life.6   
 
 Lymphedema may present immediately or years after breast cancer treatment,7 
although the majority of cases seem to appear within the first 12-18 months post-
surgery.3, 8-9 The published literature on risk factors is characterized by inconsistent 
relationships, but evidence is mounting for a few, including extent of surgery, extent 
of lymph node resection, radiation therapy, obesity, and surgical wound infection.10  
Nevertheless, it is clear that these characteristics only partially explain who develops 
lymphedema, and lymphedema can and does occur in women lacking these risk 
factors.  It is therefore possible that inherited genetic susceptibility may play a role in 
the pathogenesis of secondary lymphedema.   
 
 There has been substantial progress in identifying genes that contribute to 
development of the lymphatic vascular system during embryogenesis and its 
subsequent regulation.11-14 Some genes are now known to underlie primary 
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lymphedema,15-18 a congenital or later-onset condition that occurs in the absence of 
any known injury or medical intervention, and findings from genetic studies of 
inherited lymphedema assist with the molecular dissection of lymphatic diseases.19 
We hypothesized that genes involved in familial lymphedema (VEGFR3 (flt4), 
FOXC220 and SOX1815) and/or lymphangiogenesis in the embryo, such as VEGFC, 
VEGFD (also known as FIGF), VEGFR2 (KDR), RORC, LYVE1, ADM 
(Adrenomedullin) and PROX1,20-22 may also predispose to secondary lymphedema.  
We therefore undertook a comprehensive investigation of genetic variation in these 10 
plausible candidate genes in a cohort of breast cancer survivors, to assess the role of 
inherited genetic susceptibility in the development of secondary lymphedema after 
breast cancer.  
 
Materials and Methods 
 The study was a nested case-control design involving participants who had 
developed lymphedema within the first 18 months of their breast cancer diagnosis 
serving as cases and those without lymphedema serving as controls, identified from a 
prospective, population-based, cohort study called the ‘Pulling Through Study’ (PTS) 
conducted in Queensland, Australia.   
 
Study design and sample recruitment of the original ‘Pulling Through Study’ 
Recruitment and study design for the PTS have been described in detail 
elsewhere.9 In brief, 417 women with primary, unilateral, invasive breast cancer, 
diagnosed in 2002, were randomly selected from the Queensland Cancer Registry and 
invited to participate in the PTS.  Of these, informed consent was obtained for 68% 
(n=287). Starting at six months post-diagnosis, women were prospectively followed 
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for 12 months, with data collection procedures involving completion of a clinical 
assessment and/or self-administered questionnaire every three months. Lymphedema 
status was evaluated using the sum of arm circumferences (SOAC) method.23 A 
woman who scored a difference of >5cm between the treated and untreated sides, 
during any of the five data collection sessions between 6 and 18 months post-
diagnosis, was considered a lymphedema case. The remaining women were 
considered controls. Some of the women (26%) participated on a questionnaire-only 
basis; hence they lack objective assessments of lymphedema and therefore were not 
available for inclusion in these analyses.     
 
Design and sample recruitment of the nested case-control study 
The follow-up, nested case-control study reported here commenced 
approximately six years following the date of breast cancer diagnosis for those in the 
PTS. Of the 287 original participants, 11 withdrew from the study and 16 had died 
(identified through the Queensland Cancer Registry mortality database), leaving 260 
women to be re-contacted. Address details were checked with the electronic White 
Pages, and a change of address search was carried out through Australia Post. When 
an address could not be confirmed from these sources, the last postal address recorded 
in our files was used. The 260 potential participants were mailed an introductory letter 
(reminding them of their involvement in the prior study and inviting their 
participation in the current project), a newsletter (detailing findings from the original 
study), and a project information sheet.  
 
Following consent, collection of blood samples was arranged using the 
phlebotomist at the Queensland University of Technology (QUT) or from a local 
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commercial pathology collection center, as preferred by the participant.  
Approximately 8ml of blood was drawn from the unaffected arm into yellow-top, 
ACD tubes, and was transferred to QUT’s laboratory for processing. Upon receipt, 
samples were centrifuged, and the buffy coat (white cells) removed, aliquoted, labeled 
with a unique code and stored at -80°C. Once samples were collected and processed 
from all participants,  samples were transferred to the Queensland Institute of Medical 
Research, where genomic DNA was extracted from frozen buffy coat cells using the 
salting-out extraction method, quantified (Nanodrop Spectrophotometer ND-1000, 
Nanodrop Technologies, USA), diluted to a standardised concentration, and 12ng of 
each sample plated onto 384-well plates for genotype analysis. 
 
Genetic analyses 
 Tag single nucleotide polymorphisms (tagSNPs) that covered all known genetic 
variation in SOX18, VEGFC, VEGFD, VEGFR2, VEGFR3, RORC, FOXC2, LYVE1, 
ADM and PROX1 were selected for genotyping from HapMap data release 24/phase 
II, November 2008, NCBI build 36, dbSNP b126 (www.hapmap.org), using the 
Tagger program within Haploview version 4.124 on CEU samples only. To minimize 
the number of genotypes tested while optimizing the number of polymorphisms 
evaluated, TagSNPs were chosen with an r2≥0.8 using the pair-wise tagging approach.  
Several additional polymorphisms previously shown to have functional significance 
in primary lymphedema were also genotyped. To enhance coverage of each locus, we 
included SNPs within 5 kilobases (kb) of the 5’ and 3’ ends of each gene, based on 
the long splice variant where relevant.  
 
8 
 
SNPs were genotyped using iPLEX Gold assays on the Sequenom 
MassARRAY platform (Sequenom, San Diego, USA), as described previously.25 
There were four negative (H2O) controls per 384-well plate, and quality control 
parameters included genotype call rates >95%, inclusion of 20 duplicate samples per 
384-well plate (>5% of samples) with ≥98% concordance between duplicates, and 
Hardy-Weinberg Equilibrium p-values ≥0.05.  For assays not found to be 
polymorphic, rare-allele frequencies were confirmed using SPSmart 
(http://spsmart.cesga.es/).26 Across the 10 genes investigated, 152 SNPs were 
attempted, but 16 SNPs failed assay design or quality control standards and hence 
were excluded from further analysis.  After genotyping, the Broad Institute SNAP 
(SNP Annotation and Proxy Search) proxy search tool was used to determine SNPs 
tagged by genotyped tagSNPs for bioinformatics analyses, using the 1000 genomes 
SNP data set (http://www.broadinstitute.org/mpg/snap/ldsearch.php).27  
 
Statistical analyses 
All statistical analyses were conducted by SPSS, version 18. The genotype 
frequency distributions among cases and controls were compared using unadjusted 
logistic regression analysis. Results are reported using odds ratios (ORs) with 95% 
confidence intervals (CI).  Co-dominant mode of inheritance (i.e., rare-allele 
homozygote, heterozygote, and reference category of common-allele homozygote) 
was assumed in statistical analyses, using a trend test with 1 degree of freedom. 
Results were interpreted initially by means of p-value (<0.05). However, because of 
the limited statistical power available, it was determined a priori that ORs >2.0 (or 
equivalently, <0.5) would be acknowledged, irrespective of statistical significance, as 
long as results conformed to a pattern consistent with straightforward Mendelian 
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inheritance. This approach was considered appropriate for generation of hypotheses 
prior to seeking validation in larger studies, as is now common practice with breast 
cancer susceptibility genes.28   
 
Results 
Characteristics of the study participants 
Of the 260 women invited to participate, a further 7 were found to be 
deceased, 22 did not respond to the invitation letter and could not be contacted, and 
36 declined participation (primary reason: did not want to revisit illness). The 
remaining 195 women provided consent, 161 women provided a blood sample, and 
DNA was successfully extracted from 156 samples. Of these, 120 women had 
available data on the SOAC outcome measure used to define lymphedema status.  
Twenty-two women had evidence of lymphedema between 6-18 months post-
diagnosis, while 98 had no evidence of lymphedema. Demographic and disease 
characteristics of participants in this case-control study were comparable to the initial 
research sample (Table 1). Of note, the original cohort was shown to be representative 
of the wider Queensland breast cancer population.9    
 
Results of genetic analyses 
Table 2 provides an overview of the 10 genes under investigation. Not 
surprisingly, the more tagSNPs tested within a particular genetic locus and its 
flanking regions, the more likely we were to find a statistically significant trend test 
and/or genotype-specific ORs of a magnitude greater than 2.0 or less than 0.5. Full 
results for all SNPs tested are detailed in Supplementary Table 1. Only three loci 
revealed trend tests with p<0.05, and these same genes contained larger numbers of 
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genotype-specific ORs with extreme magnitudes that conformed with Mendelian 
expectations: VEGFR3, VEGFR2 and RORC (Table 2).   
 
Table 3 presents detailed results for VEGFR3, VEGFR2 and RORC. Multiple 
elevated (or reduced) genotype-specific ORs occurred for adjacent tagSNPs in the 5’ 
flanking region and exon/intron 1 of the three genes, where four of the five 
statistically significant results were found. VEGFR3 tagSNPs rs10464063, rs307814 
and rs307811 (ptrend=0.039 and 0.040, respectively; in high linkage disequilibrium in 
our sample set), and rs11960332, as well as the polymorphisms covered by these 
SNPs, are all located in the 5’ flanking region or intron 1 of the gene. Likewise, 
tagSNPs rs4284267, rs12128071 and rs11801866 (ptrend=0.037) are situated in these 
regions of the RORC gene, and VEGFR2 tagSNPs rs2239702 (ptrend=0.010) and 
rs7667298 tag many SNPs located in that gene’s 5’ flanking region, exon 1 and intron 
1.  Similar clustering was observed, but to a lesser extent, in the 3’ flanking region of 
VEGFR3 (rs10055319 and rs11739214, ptrend=0.020) as well as tagSNPs rs6879285, 
rs1565818 and rs11747066 in intron 29 (long splice variant)/3’ flanking region (short 
splice variant).  Other regions of possible interest due to clustering of results occurred 
in VEGFR2 at intron 2 (rs1531290 and rs4576072) and intron 7 (rs10020464, 
rs17711073, rs2034965 and rs17085326) (Table 3).   
 
Three additional genes showed minimal evidence of clustering based on the 
presence of two adjacent tagSNPs, sometimes close to an additional tagSNP, with 
genotype-specific ORs >2.0 or <0.5. These include rs11947611 and rs1485766, near 
rs6828869, all located deep in intron 4 of VEGFC; rs12089523 and rs10494972 in 
intron 4 of PROX1; and rs17318858 and rs17403620, near rs17403795, in the 3’ 
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region of LYVE1 (Supplementary Table 1). The remaining tagSNPs with ORs beyond 
the a priori thresholds of interest are individually scattered across the length of the 
tested genes.     
 
Conclusions 
The Pulling Through Study was designed to investigate the development of 
lymphedema through prospective follow-up of a cohort of Australian women recently 
treated for breast cancer. Among the women in our original cohort who presented 
with lymphedema according to objective assessment (n=67), around 40% were not in 
any of the high-risk categories, which included receiving mastectomy, 20+ nodes 
excised, or treated on the non-dominant side,9, 29 suggesting that these factors were 
partial causes at best. This follow-up study now provides suggestive evidence for the 
involvement of the genes VEGFR2, VEGFR3 and RORC in the development of 
secondary lymphedema following breast cancer treatment. One or more tagSNPs in 
each of these genes showed a statistically significant association with lymphedema, 
and these individual results appeared within clusters of tagSNPs exhibiting odds ratios 
suggestive of altered lymphedema risk. All three genes code for receptor proteins, two 
of which come from the same gene family, and the clusters of noteworthy findings 
occur in analogous gene regions with potential biological function predicted on the 
basis of bioinformatic analysis. 
 
VEGF (Vascular Endothelial Growth Factor) is a key player in angiogenesis 
and lymphangiogenesis, and interacts with numerous proteins, including VEGFC and 
VEGFD and the receptors VEGFR2 and VEGFR3.30 The VEGFC and VEGFD 
ligands stimulate lymphatic vessel growth31-32 and can ameliorate secondary 
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lymphedema in mice.33 VEGFC/D-induced lymphangiogenesis is mediated by 
VEGFR3, and VEGFR3 inhibition correlates with inhibition of lymphatic 
development and lymphedema;34 their increased expression is associated with 
metastatic disease.35 VEGFR3 has also been shown to cooperate with VEGFR2 in 
lymphatic vessel sprouting.32 In addition,  a hereditary form of lymphedema called 
Milroy disease (also known as familial primary congenital lymphedema (PCL)) has 
been attributed to non-functional forms of VEGFR3.36-37 It is therefore reasonable to 
hypothesize that more modest functional variations in these genes may predispose to 
secondary lymphedema.   
 
Bioinformatic analysis of tagSNPs located in the 5’ flanking region and 
exon/intron 1 of VEGFR2 and VEGFR3 that are associated with risk of lymphedema 
in our study revealed that these SNPs, or SNPs that are tagged by them, are predicted 
to have an effect on transcription factor binding sites.38 An example is the common 
SNP rs10464063, located upstream of VEGFR3, which displayed substantially 
elevated ORs up to 8.29 (ptrend=0.053) for the rare-allele homozygote genotype. Of the 
nine SNPs tagged by this SNP (rs10464063 included), eight are predicted to alter 
transcription factor binding sites,38 and hence may affect expression of VEGFR3.  
VEGFR2 tagSNP rs2239702 displayed the most significant ptrend -value (0.010) of all 
SNPs tested in this study, with an increased risk of secondary lymphedema up to 6.72 
for the rare-allele homozygote genotype.  Rs2239702 tags over 15 SNPs and 4 of 
these are predicted to alter transcription factor binding sites.38 To our knowledge, the 
functional effects of these SNPs have not been investigated experimentally.  
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The other interesting region of the VEGFR3 gene involves three tagSNPs in 
intron 29 of the long splice variant or the 3’ flanking region in the short version.  
TagSNPs rs6879285 and rs11747066 (which are highly correlated with each other, 
r2=0.83) both tag rs1049095, located in the 3’ untranslated region of the short splice 
variant of VEGFR3. This SNP is predicted to occur within 2 potential miRNA binding 
sites,39 alteration of which could affect protein production.  The third tagSNP, 
rs1565818, also tags the non-synonymous SNP p.R1146H (rs1130379), a common 
polymorphism reported not to be associated with PCL.18 However, the amino acid 
substitution is located in the cytoplasmic tyrosine kinase domain of VEGFR3,40 where 
various mutations have been found in PCL families.18, 36-37 The functional effects of 
p.R1146H have not been reported, although bioinformatic analysis implies that this 
residue is not highly evolutionarily conserved and therefore is most likely a benign 
alteration;41 nevertheless, the results from our study support further evaluation of this 
tagSNP and the polymorphisms it tags.     
 
The only other statistically significant association we observed between a 
tagSNP and lymphedema occurred in the RORC gene. The functional significance of 
this member of the Retinoid-related Orphan Receptor family remains unexplored in 
human secondary lymphedema;42 however, in mice, this gene is essential for 
lymphoid organogenesis.21 Also, one of its ligands, retinoic acid, recently has been 
shown to modulate lymphangiogenesis in vivo in the mouse embryo.43 Similar to the 
two VEGF receptor genes, RORC tagSNP rs11801866 is located at the 5’ end of 
RORC (in intron 1 of the commonly expressed splice variant44). Both rs11801866 and 
another interesting tagSNP in this region, rs12128071, are predicted to affect 
transcription factor binding sites.38 
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Two other genes had more limited evidence from this study for involvement in 
secondary lymphedema.  PROX1 is a human homologue of the Drosophila homeobox 
gene prospero, expressed in lymphatic vessels of adults, and essential to maintain 
lymphatic endothelial cell identity.45 However, the two tagSNPs with provocative 
findings located in intron 4 of PROX1 are now recognized to be in high linkage 
disequilibrium with each other, and although they tag a large block of many SNPs, 
none are predicted to have any functional effect.38 LYVE1 is a marker for 
commencement of lymphatic development, but the cluster of tagSNPS in the LYVE1 
3’ region (rs17318858 and rs17403620, near rs17403795) also had no predicted 
functional effects based on current knowledge.38     
 
 To our knowledge, this is the first report evaluating potential genetic 
predisposition to secondary lymphedema following breast cancer diagnosis and 
treatment. It is based on rigorous follow-up of a population-based cohort of women 
with breast cancer to detect lymphedema based on objective measurements, followed 
by a systematic and thorough exploration of polymorphisms in 10 genes of potential 
interest to the etiology of secondary lymphedema. Bonferroni correction was not 
applied, as this is considered overly conservative for a hypothesis-generating study.  
The most significant limitation of the study relates to its small sample size. Although 
67 cases had been identified via clinical assessment in the Pulling Through Study at 
the time of funding, attrition was much higher than anticipated between the 18-month 
examination and the 6-year follow-up, in part due to more difficulty obtaining blood 
samples from all previous participants and a higher mortality rate than expected 
among the women with lymphedema.46 Also, it is plausible that some of the woman 
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classified as controls had developed lymphedema between the 18-month post-
diagnosis assessment and 6-year blood draw, making it more difficult to find 
clinically and statistically significant differences between our cases and controls. 
Nevertheless, despite the limited statistical power, we identified two genetic loci from 
the same biological family, VEGFR2 and VEGFR3, and a third gene, RORC, to have 
clusters of interesting results for SNPs located in analogous parts of the genes. 
Moreover, a number of these SNPs could potentially influence transcription factor 
binding sites and protein production. Many of these polymorphisms are sufficiently 
common to be of potential public health importance if these associations are genuine, 
e.g., minor allele frequencies between 20-40% for SNPs in the two VEGFR genes.   
 
In summary, this research extends findings from primary congenital 
lymphedema and animal models to secondary lymphoedema following cancer 
diagnosis. The possibility that the three receptor genes identified confer genetic 
predisposition to secondary lymphedema following breast cancer treatment warrants 
further attention for potential replication using larger datasets. If confirmed, 
understanding the role of inherited genetic variation in lymphedema pathogenesis 
could lead to improvements in clinical management of breast cancer patients. First, 
with constant improvements in genome-wide sequencing technology and lowering of 
genotyping costs for clinical use, it is possible to envision identification of 
lymphedema molecular signature/s that could aid in the prediction and modified 
management of women at risk. This information could be used to target women for 
monitoring of lymphedema status and rapid referral to specialized care. It has been 
suggested that early detection of lymphedema may facilitate more effective 
management, resulting in reduced severity and associated disability.47 The emergence 
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of new technologies in drug design and development, combined with the 
identification of novel molecular targets specific to the onset of lymphedema, also 
may enable further development of tailored therapies, both for treatment and 
prevention of the condition. Finally, although the findings in this study are 
specifically relevant to breast cancer, if confirmed, there are implications for other 
patients at risk of secondary lymphedema following injury, melanoma, or 
gynecological, prostate, or head and neck cancers.   
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Table 1.  Demographic and disease characteristics of women from the Pulling 
Through Study and its genetic follow-up study. 
 
Original Pulling 
Through Study 
cohort (n=287) 
Participants in the 
genetics studya 
(n=120) 
 n (%)b n (%)b 
Age (years) 
<50 
>50 
 
105 (31.4) 
182 (68.6) 
 
38 (27.2) 
82 (72.8) 
Most extensive surgery  
CLEc 
Mastectomy 
185 (64.9) 
102 (35.1) 
83 (69.6) 
37 (30.4) 
Largest tumor size 
<16mm 
16+mm 
 
171 (60.3) 
116 (39.7) 
 
78 (65.8) 
42 (34.2) 
Number of nodes positive  
None removed 
None positive 
1-3 
4+ 
Unavailable 
38 (13.1) 
158 (55.9) 
59 (20.1) 
29 (9.8) 
3 (1.1) 
17 (14.1) 
66 (56.6) 
28 (22.2) 
9 (7.2) 
0 (0.0) 
Overall histologic grade  
24 
 
One 
Two 
Three 
Unavailable 
76 (26.7) 
90 (31.7) 
91 (30.7) 
30 (10.8) 
35 (29.4) 
33 (27.5) 
41 (33.5) 
11   (9.6) 
Histologic type 
Infiltrating ductal 
Infiltrating Lobular 
Other 
 
210 (72.6) 
44 (15.6) 
33 (11.7) 
 
88 (73.0) 
14 (12.0) 
18 (15.0) 
a those from the original cohort with sufficient data to calculate cumulative burden of 
lymphedema between 6-18 months post-diagnosis and who provided a blood sample; 
b results have been appropriately weighted (<50 years, 1.0; >50 years, 1.3) for 
oversampling of younger women; c CLE, complete local excision. 
25 
 
Table 2.  Overview of genetic analyses and results for the 10 candidate genes hypothesized to influence risk of secondary lymphedema following 
breast cancer treatment 
Gene Gene regiona Sizeb  
(kilobases)
# tagSNPs to 
cover HapMap 
SNPs in gene 
regionc 
# tagSNPs 
testedd 
 
Trend test 
p<0.05 (# of 
tagSNPs) 
Genotype-
specific ORe 
>2.0 or <0.5 (# 
of tagSNPs) 
Mendelian 
patternf of 
‘extreme’ 
ORs   
(# tagSNPs) 
VEGFC chr4:177718895..177599691 119.2 kb 17 tagSNPs to 
capture 126 SNPs 
17 0 5 4 
VEGFR2 chr4:55939427..55996762  57.3 kb 29 tagSNPs to 
capture 55 SNPs 
24 1 12 11 
VEGFR3 chr5:180023507..180081624  58.1 kb 33 tagSNPs to 
capture 52 SNPs 
32 3 14 13 
RORC chr1:151773548..151809348  35.8 kb 23 tagSNPs to 22 1 9 8 
26 
 
capture 39 SNPs 
VEGFD chrX:15358718..15407577  48.9 kb 7 tagSNPs to 
capture 36 SNPs 
7 0 4 2 
PROX1 chr1:214156860..214214761  57.9 kb 13 tagSNPs to 
capture 35 SNPs 
11 0 5 2 
LYVE1 chr11:10574413..10595365  20.9 kb 11 tagSNPs to 
capture 25 SNPs 
8 0 4 3 
ADM chr11:10321642..10333924  12.3 kb 8 tagSNPs to 
capture 11 SNPs 
7 0 1 1 
SOX18 chr20:62674081..62685979  11.9 kb 3 tagSNPs to 
capture 3 SNPs 
3 + 
3SNPsd 
0 3 0 
FOXC2 chr16:86595857..86607536  11.7 kb 2 tagSNPs to 
capture 2 SNPs 
2 0 0 0 
a Co-ordinates from NCBI37 assembly; b An extra 5kb on each end of the genetic locus was included for TagSNP selection; c As determined by 
Haploview version 4.2 using HapMap data release 24/phaseII, November 2008, on NCBI B36 assembly, dbSNP 126; d Differences in # tagSNPs 
27 
 
from # SNPs tested are due to failures in design or genotyping (16 of 152 total SNPs attempted). Additional SNPs were chosen to capture 
genetic variation in the SOX18 gene more completely; e Odds ratio (OR) reveals at least a doubling or halving of lymphedema risk for women 
who are heterozygous and/or homozygous for the rare allele; f Pattern of odds ratios across the three genotypes conforms with co-dominant, 
dominant or recessive mode of inheritance. 
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Table 3 Associations between tagSNPsa within VEGFR3, VEGFR2 and RORC (odds ratio (OR) with 95% confidence intervals (CI)) and 
presence of lymphedema between 6- and 18-months following breast cancer surgery  
 
Genotype  Nb OR  95% CI  p‐
value 
Nb OR 95% CI  p‐
value 
Nb OR 95% CI p‐
value 
VEGFR3      VEGFR2    RORC   
rs10464063 A>G    
    AA 
    AG
    GG
MAFd = 0.49 
30
49
27
 
 
1.00 
7.44 
8.29 
 
‐ 
0.90,61.40
0.93,74.05 
 
0.06 
0.06 
rs2239702 G>A
  GG 
  GA
  AA 
MAF = 0.25 
61 
37 
8 
1.00 
3.60 
6.72 
 
‐ 
1.10,11.76
1.23,36.74 
 
0.03 
0.03 
rs11204897 T>C
                    TT 
                   TC 
                   CC 
MAF = 0.12 
90
26
1
 
1.00
1.19
c 
‐ 
0.39,3.66 
c 
 
 
0.76 
1.00 
    Trend test      0.05  Trend test   0.01    Trend test 0.29 
rs307805 A>G 
  AA
  AG
  GG
99
18
1
 
1.00 
0.53 
c 
 
‐ 
0.11,2.49 
c 
 
0.42 
1.00 
rs7667298 G>A
  GG 
  GA
  AA 
35
59
24
1.00 
1.78 
2.85 
 
‐ 
0.52,6.08 
0.64,10.39 
 
0.36 
0.18 
rs4845366 C>G
    CC
    CG
    GG
71
36
9 
1.00
0.81
0.51
‐ 
0.28,2.34 
0.06,4.41 
 
 
0.70 
0.54 
29 
 
 
Genotype  Nb OR  95% CI  p‐
value 
Nb OR 95% CI  p‐
value 
Nb OR 95% CI p‐
value 
MAF = 0.08  MAF = 0.45 MAF = 0.23
    Trend test      0.35  Trend test   0.18    Trend test 0.50 
rs307814 G>A*
  GG
  GA
   AA
MAF = 0.40   
38
54
17
 
 
1.00 
1.93 
4.64 
 
‐ 
0.56,6.70 
1.10,19.50 
 
0.30 
0.04 
rs12502008 C>A
     CC
     CA
     AA
MAF = 0.37 
51
47
20 
1.00 
1.11 
0.82 
 
‐ 
0.40,3.07 
0.20,3.42 
 
0.85 
0.79 
rs4284267 A>T
    AA
    AT
    TT
MAF = 0.04 
108
10
0 
1.00
0.49
‐ 
‐ 
0.06,4.08 
‐ 
 
 
0.51 
    Trend test      0.04     Trend test   0.87    Trend test 0.51 
rs307811 C>T*
  CC
  CT
  TT 
MAF = 0.39   
41
47
18
14 
 
1.00 
1.62 
4.63 
 
‐ 
0.44,5.98 
1.12,19.19 
 
0.47 
0.04 
rs1531290 C>T
  CC 
  CT
  TT 
MAF = 0.50 
30
50
30
 
1.00 
2.54 
2.25 
 
‐ 
0.65,9.97 
0.51,9.99 
 
0.18 
0.29 
rs12128071 C>T
  CC 
  CT
  TT 
MAF = 0.07 
97
11
2
 
1.00
1.05
4.71 
‐ 
0.21,5.28 
0.28,79.01 
 
 
0.96 
0.28 
30 
 
 
Genotype  Nb OR  95% CI  p‐
value 
Nb OR 95% CI  p‐
value 
Nb OR 95% CI p‐
value 
    Trend test      0.04  Trend test   0.32   Trend test  0.43 
31 
 
 
rs11960332 C>T
  CC
CT
  TT 
MAF = 0.15   
87
25
5
 
 
1.00 
0.31 
c 
 
‐ 
0.07,1.44 
c 
 
0.14 
0.99 
rs4576072 A>G
  AA 
  AG
  GG 
MAF = 0.16 
83
32
3
 
1.00 
0.37 
c 
 
‐ 
0.10,1.37 
c 
 
0.14 
0.99 
rs3811417 A>G
    AA
    AG
    GG
MAF = 0.14 
87
29
2 
1.00
0.66
c 
‐ 
0.20,2.15 
c 
 
 
0.49 
0.99 
    Trend test      0.08  Trend test   0.09    Trend test 0.36 
rs10479476 C>A
     CC
     CA
     AA
MAF = 0.02 
107
2
1 
 
1.00 
c 
c 
 
‐ 
c 
c 
 
0.99 
1.00 
rs6837735 G>A
     GG
     GA
     AA
MAF = 0.16 
81
32
3 
1.00 
1.02 
c 
 
‐ 
0.36,2.90 
c 
 
0.98 
0.99 
rs11801866 A>T
      AA 
      AT
      TT
MAF = 0.07 
94
16
0 
1.00
3.43 
‐ 
1.07,10.94
‐ 
 
 
0.04 
     Trend test      0.99     Trend test   0.68   Trend test  0.04 
rs11748431 C>T
     CC
     CT
59
46
 
1.00 
1.06 
 
‐ 
0.40,2.83 
 
0.90 
rs2305949 G>A
     GG
     GA
67
43
1.00 
0.67 
 
‐ 
0.24,1.93 
 
0.46 
rs6685811 G>A
GG
GA
118
1
1.00
c 
‐ 
c 
 
 
1.00 
32 
 
     TT
MAF = 0.29 
11 0.44  0.05,3.77  0.45     AA
MAF = 0.25 
8 1.39 0.25,7.66  0.71 AA
MAF = 0.004 
0 ‐ ‐  
     Trend test      0.63     Trend test   0.85  Trend test 1.00 
rs307806 C>T 
     CC
     CT
     TT
MAF = 0.11 
92
24
1 
 
1.00 
0.88 
c 
 
‐ 
0.27,2.92 
c 
 
0.84 
1.00 
rs7692791 A>G
     AA
     AG
     GG
MAF = 0.46 
31
56
23 
1.00 
0.35 
0.52 
 
‐ 
0.12,1.06 
0.14,1.94 
 
0.06 
0.33 
rs4845604 C>T
    CC
    CT
    TT
MAF = 0.12 
89
29
0 
1.00
1.71
‐ 
‐ 
0.61,4.75 
‐ 
 
 
0.31 
     Trend test      0.71    Trend test   0.21    Trend test 0.31 
rs4700966 A>G
     AA
     AG
     GG
MAF = 0.09 
96
22
0 
 
1.00 
1.03 
‐ 
 
‐ 
0.31,3.44 
‐ 
 
0.96 
rs2305948 G>A
     GG
     GA
     AA
MAF = 0.13 
90
23
3 
1.00 
1.29 
c 
 
‐ 
0.42,3.97 
c 
 
0.66 
0.99 
rs12030974 C>T
    CC
    CT
    TT
MAF = 0.19 
79
33
6 
1.00
1.03
0.93 
‐ 
0.36,2.97 
0.10,8.58 
 
 
0.95 
0.95 
     Trend test      0.96     Trend test   0.90    Trend test 1.00 
33 
 
 
rs2290983 T>C
     TT
     TC
     CC
MAF = 0.39 
39
43
17 
 
1.00 
0.54 
0.44 
 
‐ 
0.17,1.69 
0.09,2.32 
 
0.29 
0.34 
rs10020464 G>A
     GG 
     GA
     AA
MAF = 0.31 
52
48
10 
1.00 
0.57 
0.37 
 
‐ 
0.20,1.59 
0.04,3.23 
 
0.28 
0.37 
rs11204894 T>C
    TT
    TC
    CC
MAF = 0.20 
70
36
4 
1.00
1.79
c 
‐ 
0.66,4.82 
c 
 
 
0.25 
0.99 
     Trend test      0.24     Trend test   0.20    Trend test 0.66 
rs3797102 T>C
     TT
     TC
     CC
MAF = 0.47 
33
60
25 
 
1.00 
1.63 
2.29 
 
‐ 
0.47,5.59 
0.57,9.20 
 
 
0.44 
0.24 
rs11941492 G>A
     GG
     GA
     AA
MAF = 0.26 
67
41
10 
1.00 
1.11 
0.51 
 
‐ 
0.41,3.00 
0.06,4.41 
 
0.84 
0.45 
rs11578418 C>T
    CC
    CT
    TT
MAF = 0.07 
94
16
0 
1.00
2.39
‐ 
‐ 
0.73,7.89 
‐ 
 
 
0.15 
     Trend test      0.24     Trend test   0.75    Trend test 0.15 
rs307823 A>G 
     AA
     AG
81
33
 
1.00 
0.56 
 
‐ 
0.17,1.82 
 
0.34 
rs17711073 A>G
     AA
     AG
96
20
1.00 
0.45 
 
‐ 
0.10,2.11 
 
0.31 
rs6693413 T>C
    TT
    TC
35
57
1.00
0.96
‐ 
0.33,2.76 
 
 
0.93 
34 
 
     GG
MAF = 0.17 
4 1.35  0.13,13.90 0.80     GG
MAF = 0.09 
1 c c 
 
1.00    CC
MAF = 0.44 
22 0.63 0.15,2.75 0.54 
     Trend test      0.57     Trend test   0.27    Trend test 0.82 
rs3797104 A>G
     AA
     AG
     GG
MAF = 0.12 
91
25
1 
 
1.00 
0.35 
c 
 
‐ 
0.08,1.64 
c 
 
0.18 
1.00 
rs2034965 C>T
  CC 
  CT
  TT 
MAF = 0.25 
66
38
9
 
1.00 
2.62 
2.41 
 
‐ 
0.89,7.73 
0.42,13.94 
 
0.08 
0.33 
rs3790515 G>A
    GG
    GA
    AA
MAF = 0.11 
94
22
2 
1.00
0.40
c 
‐ 
0.09,1.84 
c 
 
 
0.24 
0.99 
     Trend test      0.64  Trend test   0.11    Trend test 0.18 
rs307826 A>G 
     AA
     AG
     GG
MAF = 0.13 
89
28
1 
 
1.00 
0.99 
c 
 
‐ 
0.33,3.00 
c 
 
0.99 
1.00 
rs17085326 G>A
  GG 
  GA
  AA 
MAF = 0.06 
96
13
0
 
1.00 
2.22 
 
 
‐ 
0.61,8.11 
 
0.23 
rs1521186 C>T
    CC
    CT
    TT
MAF = 0.48 
30
50
25 
1.00
1.06
1.63 
‐ 
0.28,3.97 
0.39,6.85 
 
 
0.93 
 0.51 
     Trend test      0.86     Trend test   0.23    Trend test 0.51 
35 
 
 
rs307827 G>A 
     GG
     GA
     AA
MAF = 0.13 
88
27
2 
 
1.00 
1.02 
c 
 
‐ 
0.34,3.11 
c 
 
0.97 
0.99 
rs7654599 A>G
     AA 
     AG
     GG
MAF = 0.39 
46
49
21 
1.00 
1.22 
0.76 
 
‐ 
0.43,3.42 
0.19,3.34 
 
0.71 
0.75 
rs939595 G>T
    GG
    GT
    TT
MAF = 0.34 
51 
52 
14 
1.00
0.59
0.48 
‐ 
0.20,1.79 
0.06,4.10 
 
 
0.35 
0.50 
 
     Trend test      0.78     Trend test   0.88    Trend test 0.29 
rs2242208 C>T
     CC
     CT
     TT
MAF = 0.03 
103
7
0 
 
1.00 
1.89 
‐ 
 
‐ 
0.34,10.52 
 
0.47 
rs13135562 G>C
     GG
     GC
     CC
MAF = 0.03 
107
8
0 
1.00 
0.62 
‐ 
 
‐ 
0.07,5.34 
‐ 
 
0.66 
rs10494269 G>C
    GG
    GC
    CC
MAF =  0.23 
51
52
14 
1.00
1.11
0.78 
‐ 
0.20,1.79 
0.06,4.10 
 
 
0.35 
0.50 
 
     Trend test      0.47     Trend test   0.66    Trend test 0.29 
rs13172346 C>T
     CC
     CT
69
43
 
1.00 
0.57 
 
‐ 
0.19,1.72 
 
0.32 
rs12505758 A>G
     AA
     AG
88
19
1.00 
0.46 
 
‐ 
0.10,2.16 
 
0.32 
rs1521177 A>C
    AA
    AC
32 
55 
1.00
0.52
‐ 
0.16,1.65 
 
 
0.27 
36 
 
     TT
MAF = 0.23 
5 6.46  0.98,42,70 0.05     GG
MAF = 0.11 
3 c c  0.99    CC
MAF = 0.44 
19 0.67 0.15,2.97 0.60 
     Trend test      0.54     Trend test   0.21    Trend test 0.46 
rs6879285 T>C^
     TT
     TC
     CC
MAF = 0.32 
44
57
6 
 
1.00 
1.19 
3.17 
 
‐ 
0.39,3.63 
0.47,21.24 
 
0.76 
0.24 
rs6838752 A>G
     AA 
     AG
     GG
MAF = 0.28 
60
50
8 
1.00 
1.42 
1.89 
 
‐ 
0.53,3.82 
0.33,10.87 
 
0.49 
0.48 
rs12045886 A>G
    AA
    AG
    GG
MAF = 0.25 
61
49
4 
1.00
0.47
c 
‐ 
0.17,1.33 
c 
 
 
0.15 
0.99 
     Trend test      0.36     Trend test   0.38    Trend test 0.09 
rs17080412 G>C
     GG
     GC
     CC
MAF = 0.03 
104
6
0 
 
1.00 
c 
‐ 
 
‐ 
c 
‐ 
 
0.99 
rs1458831 A>G
     AA
     AG
     GG
MAF = 0.13 
89
25
3 
1.00 
0.32 
c 
 
‐ 
0.07,1.48 
c 
 
0.14 
0.99 
rs3828057 G>A
    GG
    GA
    AA
MAF=0.46 
35
56
25 
1.00
3.56
2.03 
‐ 
0.94,13.43
0.41,10.01 
 
 
0.06 
0.38 
     Trend test      0.99     Trend test   0.10    Trend test 0.34 
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rs1565818 C>G
     CC
     CG
     GG
MAF = 0.08 
89
14
1 
 
1.00 
0.38 
c 
 
‐ 
0.05,3.13 
c 
 
0.37 
1.00 
rs7671745 C>T
     CC
     CT
     TT
MAF = 0.41 
44
50
22 
1.00 
1.67 
0.53 
 
‐ 
0.59,4.71 
0.10,2.79 
 
0.33 
0.45 
rs9826 A>G
    AA
    AG
    GG
MAF =0.34 
55 
48 
16 
1.00
0.46
0.46 
‐ 
0.16,1.33 
0.09,2.30 
 
 
0.15 
0.35 
     Trend test      0.32    Trend test   0.74    Trend test 0.16 
rs11747066 C>T^
     CC
     CT
     TT
MAF = 0.29 
56
56
6 
 
1.00 
1.30 
6.00 
 
‐ 
0.47,3.60 
1.03,35.11 
 
0.61 
0.05 
rs1531289 G>A
     GG
     GA
     AA
MAF = 0.25 
63 
37 
8 
1.00 
1.70 
0.76 
 
‐ 
0.62,4.68 
0.08,6.84 
 
0.30 
0.80 
 
     Trend test      0.12     Trend test   0.64  
rs6877011 G>C
     GG
     GC
97
12
 
1.00 
1.69 
 
‐ 
0.41,6.93 
 
0.47 
rs10008360 C>T
  CC 
  CT
115
3
1.00 
2.38 
 
‐ 
0.21,27.48
 
0.49 
 
38 
 
     CC
MAF = 0.06 
1 c  c  1.00 TT
MAF = 0.01 
0 ‐ ‐ 
     Trend test      0.11   Trend test   0.49  
rs2279622 G>A
     GG
     GA
     AA
MAF = 0.08 
99
18
1 
 
1.00 
0.97 
c 
 
‐ 
0.25,3.70 
c 
 
0.96 
1.00 
rs12642307 A>G
     AA
     AG
     GG
MAF = 0.36 
48
53
16 
1.00 
1.02 
1.67 
 
‐ 
0.36,2.91 
0.43,6.51 
 
0.97 
0.46 
 
     Trend test      0.39     Trend test   0.54  
rs307822 G>A 
     GG
     GA
     AA
MAF = 0.13 
81
20
4 
 
1.00 
0.92 
1.74 
 
‐ 
0.24,3.61 
0.17,18.09 
 
0.91 
0.64 
rs10006115 C>A
     CC
     CA
     AA
MAF = 0.02 
111
5
0 
1.00 
1.14 
‐ 
 
‐ 
0.12,10.73
‐ 
 
 
0.91 
 
     Trend test      0.81     Trend test   0.91  
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rs10055319 G>C
  GG 
  GC
  CC 
MAF = 0.17 
80
35
3
 
 
1.00 
1.29 
2.58 
 
‐ 
0.47,3.57 
0.22,30.55 
 
0.63 
0.45 
   
 
 
 
  Trend test      0.44    
rs11739214 G>C
  GG 
  GC
  CC
MAF = 0.30 
57
51
10
 
 
1.00 
2.34 
5.67 
 
‐ 
0.80,6.87 
1.24,25.96 
 
0.12 
0.03 
   
    Trend test      0.02    
a Results for tagSNPs with no variation in our sample are not shown, including rs432475 for VEGFR3, and for RORC: rs17582155, 
rs7546811; b Sample sizes vary slightly across tagSNPs due to missing values from random technical errors; c Insufficient data for 
meaningful analysis; d MAF refers to minor allele frequency 
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*according to HapMap, rs307814 and rs307811 are in high LD but below the r2=0.80 threshold (r2=0.79). Our analyses reveal the two 
SNPs to be in high LD (r2=0.90) 
^according to HapMap, rs6879285 and rs11747066 are in LD (r2=0.83) 
Shaded boxes highlight clusters of results (in terms of physical location within the gene) that meet a priori criteria of interest, namely 
ptrend<0.05 or extreme odds ratio (<0.5 or >2.0); see results for further description 
 
 
 
 
